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a b s t r a c t
The aim of this work was to develop and validate a new microbiological assay to determine potency
of linezolid in injectable solution. 24 factorial and central composite designs were used to optimize
the microbiological assay conditions. In addition, we estimated the measurement uncertainty based
on residual error of analysis of variance of inhibition zone diameters. Optimized conditions employed
4 mL of antibiotic 1 medium inoculated with 1% of Staphylococcus aureus suspension, and linezolid
in concentrations from 25 to 100 mg mL1. The method was speciﬁc, linear (Y¼10.03Xþ5.00 and
Y¼9.20Xþ6.53, r2¼0.9950 and 0.9987, for standard and sample curves, respectively), accurate (mean
recovery¼102.7%), precise (repeatability¼2.0% and intermediate precision¼1.9%) and robust. Micro-
biological assay's overall uncertainty (3.1%) was comparable to those obtained for other microbiological
assays (1.7–7.1%) and for determination of linezolid by spectrophotometry (2.1%) and reverse-phase
ultra-performance liquid chromatography (RP-UPLC) (2.5%). Therefore, it is an acceptable alternative
method for the routine quality control of linezolid in injectable solution.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Antimicrobial agents are one of the most used substance classes
worldwide. They are used as preservatives in foods, medicines and
industrial products, in hospital and industrial disinfection of surfaces,
instruments and tissues and in the treatment of infectious diseases.
The effectiveness of antimicrobial agents depends on the identity,
purity and their activity against the speciﬁc microorganism. The
clinical use of antimicrobial agents is an issue, particularly due to
the emergence of resistant strains [1–3]. On the other hand, only a
few new molecules have been developed and approved for clinical
use in recent decades. Most of these new antibiotics belong to
known classes, such as β-lactam and quinolone, and just one of
these belongs to a new class, oxazolidinone [1–3].
Linezolid belongs to a new class of antibiotics, oxazolidinones,
and it was approved for clinical use in 2000. The mechanism of
action of oxazolidinones appears to be unique in that it blocks the
initiation of protein synthesis, not of the latter steps. Chemically,
linezolid is an (S)-N-[[3-[3-ﬂuoro-4-(4-morpholinyl)phenyl]-2-oxo-
5-oxazolidinyl]methyl] acetamide (Fig. 1). It is used to treat serious
infections caused by Gram-positive bacteria resistant to several
antibiotics, including vancomycin-resistant enterococci (VRE) and
methicillin-resistant Staphylococcus aureus (MRSA) [1–3].
The methods reported in the literature for determination of
linezolid include ultraviolet (UV) spectrophotometry, high perfor-
mance liquid chromatography (HPLC) UV-detection and ﬂuorescence
detection, capillary electrophoresis and thin-layer chromatography
(TLC) followed by densitometric analysis and microbiological assay
[4–11]. Despite that these methods present good reproducibility and
are widely used in pharmaceutical quality control laboratories, they
do not allow for evaluating antimicrobial activity (potency) [12–14].
The potency of antimicrobial agents may be evaluated accord-
ing to their ability to inhibit microbial growth in appropriate
conditions. In agar diffusion microbiological assay, two pheno-
mena occur simultaneously: 1) diffusion of antimicrobial agent;
and 2) microbial growth. According to Fick's law of diffusion,
antimicrobial concentration can be estimated as a function of
the initial concentration (at the well, cylinder or paper disc), a
diffusion constant, time and the square of diffusion distance.
Simultaneously, microbial growth occurs as a function of the
initial burden load (inoculum amount), lag phase time, generation
time and time of incubation [15–19]. A reduction in the antimi-
crobial activity can reveal subtle alterations that cannot be demon-
strated through chemical methods. In addition to this, biological
assays do not require specialized equipment or high toxicity
solvents [18–23].
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Traditionally, development of analytical methods has involved
monitoring the inﬂuence of one factor at a time on the experi-
mental results [24–26]. This approach may be tedious and slow; in
addition, it does not include the interactive effects among the
variables studied [24–26]. Factorial design and response surface
methodology may be useful tools in the development of analytical
methods, since they allow the evaluation of multiple factors
in experimental results [24–26]. When a microbiological assay
is performed, it is highly advisable to adopt an experimental
design that, without further effort, delivers the best results and
provides solid assay validity. The factorial design and response sur-
face methodology may be useful in optimizing conditions which
provide better results concerning the linearity, regression and
parallelism of standard and sample curves [27,28].
Moreover, it is also important to assess the quality of the
microbiological assay results. One useful measure of this is
measurement uncertainty [29–34]. Measurement uncertainty pro-
vides additional information that may be useful for compliance or
non-compliance decisions [34–39]. The uncertainty in the results
may arise from many possible sources, including sampling, matrix
effects and interferences, environmental conditions, uncertainties
of mass and volumetric equipments, uncertainties of spectro-
photometric and chromatographic equipments, uncertainties of
biological and microbiological responses, purity of reagents and
chemical reference substances, method validation and random
variability [40–55].
The aim of this work is to develop and optimize a micro-
biological assay for linezolid, using factorial design and response
surface methodology. This work also aims at validating the
microbiological assay and evaluating its measurement uncertainty.
2. Materials and methods
2.1. Instruments
Calibrated volumetric ﬂasks and pipettes, stainless steel cylin-
ders, and a microbiological incubator (Nova Ética, Brazil) were
used in the microbiological assay. Also, a calibrated inhibition zone
reader (Haloes caliper, IUL) with accuracy of 0.1 mm was used in
the microbiological assay. The experimental design and statistical
analysis of the data were performed using a Minitab™ 16 software.
2.2. Reagents and reference materials
Antibiotic 1 culture medium (Anti 1, beef extract 1.5 g/L, yeast
extract 3.0 g/L, pancreatic digest of casein 4.0 g/L, peptone 6.0 g/L,
dextrose 1.0 g/L and agar 15.0 g/L) was obtained from AES labora-
tory (France). Tryptic soy agar culture medium (TSA, pancreatic
digest of casein 15.0 g/L, papaic digest of soybean 5.0 g/L, sodium
chloride 5.0 g/L and agar 15.0 g/L) was obtained from Difco/BD
(USA). Sodium chloride was obtained from INLAB (Brazil). Line-
zolid working standard (Sigma-Aldrich, Lot 020M4707V) was char-
acterized by assessment of its identiﬁcation and purity using
nuclear magnetic resonance (NMR), infrared spectroscopy (FTIR)
and thermo-gravimetric analysis (TGA) in order to be used in the
development and validation of the microbiological assay. Zyvox
samples were obtained from Pﬁzer. Standard and sample solutions
were diluted using a phosphate buffer pH 6.0 (potassium phos-
phate monobasic 8.0 g/L and potassium phosphate dibasic 2.0 gL).
S. aureus (ATCC 6538) and Kocuria rhizophila (ATCC 9341) were
obtained from the Instituto Adolfo Lutz (São Paulo, Brazil).
2.3. Development and optimization of microbiological assay
A 24 factorial design was used to verify the most important
parameters among choice microorganism-test, choice of culture
media, seeded layer volume, inoculum amount and concentra-
tion of linezolid. The conditions of 24 factorial experiments are
described in Table 1. Microorganism-test and culture medium
were chosen based on the factorial design.
Then, a central composite design (CCD – surface response meth-
odology) was used to optimize the volume of seeded culture medium,
inoculum amount and concentration of linezolid employed for
microbiological assay. The conditions of CCD are listed in Table 2.
Optimized conditions were established based on estimated inhibition
zone sizes that provide good regression, linearity and parallelism of
standard and sample curves.
2.4. Validation and uncertainty of microbiological assay
The method we developed and optimized was validated by
assessing speciﬁcity/selectivity, linearity, precision (repeatability
and intermediate precisions) and accuracy. Standard and sample
curves were also tested for regression, lack of deviation and lack of
parallelism. Robustness was evaluated using the central composite
design during development and the optimization microbiological
assay method. The inﬂuence of the volume of seeded culture
medium and inoculum used for microbiological assay was eval-
uated simultaneously. In addition, the measurement uncertainty of
linezolid potency was estimated, based on the residual error of
analysis of variance for inhibition zones diameters of standards
and samples.
Fig. 1. Chemical structure of linezolid.
Table 1
A 24 factorial design to establish the most signiﬁcant factors affecting the inhibition
zone diameters of linezolid microbiological assay.
Microorganisms Culture media Volume of
seeded culture
mediuma (mL)
Inoculum
proportionb (%)
Staphylococcus aureus TSA 4.0 1.0
Staphylococcus aureus TSA 4.0 2.0
Staphylococcus aureus TSA 5.0 1.0
Staphylococcus aureus TSA 5.0 2.0
Staphylococcus aureus Anti 1 4.0 1.0
Staphylococcus aureus Anti 1 4.0 2.0
Staphylococcus aureus Anti 1 5.0 1.0
Staphylococcus aureus Anti 1 5.0 2.0
Kocuria rhizophila TSA 4.0 1.0
Kocuria rhizophila TSA 4.0 2.0
Kocuria rhizophila TSA 5.0 1.0
Kocuria rhizophila TSA 5.0 2.0
Kocuria rhizophila Anti 1 4.0 1.0
Kocuria rhizophila Anti 1 4.0 2.0
Kocuria rhizophila Anti 1 5.0 1.0
Kocuria rhizophila Anti 1 5.0 2.0
a Aliquots of 21 mL of the Anti 1 or TSA are employed as base layer.
b Suspension prepared in 0.9% sodium chloride solution and diluted to obtain
2573% of transmittance at 580 nm. Linezolid concentrations of 25, 50 and
100 mg mL1are used.
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3. Results and discussion
3.1. Development and optimization of microbiological assay
The development and optimization of microbiological assay for
linezolid were performed using the factorial design and response
surface methodology. The 24 factorial design was performed
(Table 1) to establish the most signiﬁcant factors in the inhibition
zone diameter. According to the Pareto chart results (Fig. 2),
microorganism test and antibiotic concentration have a greater
inﬂuence on the inhibition zone diameters of the linezolid micro-
biological assay. We must pay attention to the fact that the
microorganisms showed a greater inﬂuence in the inhibition zone
diameters than antibiotic concentration. In other words, the choice
of the microorganism to be used in the microbiological assay is a
critical issue.
In microbiological agar diffusion method for antibiotics, two
phenomena occur simultaneously: a) the diffusion of antibiotic;
and b) microbiological growth. The inhibition zone diameters
depend on these two phenomena. The susceptibility of micro-
organism-test may signiﬁcantly affect the inhibition zone dia-
meters (Fig. 3 – Microorganism). K. rhizophila seems to be more
susceptible to linezolid than S. aureus. However, delimitation of
halos using S. aureus was better, because the growth was denser.
The culture medium composition may affect microbial growth
and antibiotic diffusion, which may affect the inhibition zone
diameters. Higher contents of agar, dextrose and salt may reduce
the diffusion of the antibiotic, which will decrease the inhibition
zone diameters. On the other hand, the amount of nutrients may
reduce the lag phase period and/or generation time of micro-
organisms, which will decrease the inhibition zone diameters.
Culture medium pH may also affect both microbial growth and
antibiotic diffusion. The slight differences among the inhibition
zone diameters using TSA and Anti 1 may be explained by their
differences in composition and pH (Fig. 3 – Culture medium) [15].
S. aureus and antibiotic 1 (Anti 1) were adopted as microorganism
and culture medium, respectively, based on 24 factorial design
results.
Table 2
Response surface methodology used to optimize the microbiological assay for
linezolid with respect to volume of culture medium and proportion of inoculum,
considering Staphylococcus aureus and antibiotic 1 as microorganism and culture
medium, respectively.
Volume of seeded culture
mediuma (mL)
Inoculum
proportionb (%)
Antibiotic concentration
(mg mL1)
4.0 1.0 25, 50 and 100
4.0 2.0 25, 50 and 100
5.0 1.0 25, 50 and 100
5.0 2.0 25, 50 and 100
4.5 1.5 25, 50 and 100
4.5 1.5 25, 50 and 100
4.5 1.5 25, 50 and 100
4.5 1.5 25, 50 and 100
4.5 1.5 25, 50 and 100
a Aliquots of 21 mL of the Anti 1 or TSA were employed as base layer.
b Suspension prepared in 0.9% sodium chloride solution and diluted to obtain
2573% of transmittance at 580 nm.
Fig. 2. Pareto chart shows inﬂuence of microorganism, culture medium, volume of
seeded culture medium, inoculum and antibiotic concentration on the inhibition
zone diameters of linezolid microbiological assay.
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Fig. 3. Main effects plot to show the inﬂuence of microorganism, culture medium, volume of seeded culture medium and inoculum on the inhibition zone diameters of
linezolid microbiological assay.
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In addition to culture medium composition, the thickness of
the seeded layer (which may be measured as the volume of seeded
culture medium) is an important issue in the inhibition zone
diameters. According to our results (Fig. 3 – Volume), the higher
the volume of seeded culture medium, the smaller the inhibition
zone diameters. These results are in accordance with the agar
diffusion theory [15]. Double-layer (seed layer and base layer)
plates are often used in microbiological assay, due to their advan-
tages regarding monolayer plates (seed layer only). Base layer
(prepared with about 20–21 mL) will provide nutritional demand
of microbial growth that occurs in a very thin seeded layer
(prepared with about 4–5 mL). The thinner the seed layer the
bigger the inhibition zones, and consequently, the more sensitive
the microbiological assay is. Moreover, the higher the microorgan-
ism inoculum the smaller the inhibition zone diameters, because a
higher amount of antibiotic will be needed to inhibit the microbial
growth. Our results are in accordance with these (Fig. 3 –
Inoculum) [15]. Microbial suspension was prepared in 0.9% sodium
chloride solution and diluted to obtain 2573% of transmittance at
580 nm to ensure the reproducibility of microorganism inoculum
(about 106 CFU mL1).
A surface response methodology was used to optimize the
microbiological assay for linezolid with respect to the volume of
culture medium, proportion of inoculum and antibiotic concentra-
tion (Table 2). First, a full quadratic model was adopted to explain
the inhibition zone diameters based on the volume of culture
medium, proportion of inoculum and antibiotic concentration.
Although the full quadratic model showed good adjustment
(p¼0.985 for lack-of-ﬁt and r2¼0.9221), most of the quadratic
factors and all of interactions were not signiﬁcant. Therefore,
an incomplete quadratic model is adjusted, as shown in Table 3.
Also, three-dimensional plots of the response surface (inhibition
zone diameters) as a function of volume of medium, proportion
of inoculum and linezolid concentration are shown in Fig. 4.
Response optimization analysis indicates the following experi-
mental conditions: (a) S. aureus (ATCC 6538) as microorganism;
(b) antibiotic medium 1 as culture medium; (c) double-layer
plates prepared with 21.0 mL of base layer and 4.0 mL of seed
layer; (d) seed layer inoculated with a proportion of 1.0% (v/v) of
microbial suspension (2573% of transmittance at 580 nm);
(e) incubation of plates at 3771 1C for 18–24 h; and (f) linezolid
concentrations of 25, 50 and 100 mg mL1.
3.2. Validation and uncertainty of microbiological assay
Using the optimized conditions established, the method was
validated by assessing speciﬁcity/selectivity, linearity, precision
(repeatability and intermediate precision) and accuracy. There was
no interference of excipients of linezolid pharmaceutical preparation,
which indicates the speciﬁcity/selectivity of microbiological method.
The microbiological assay showed good linearity in the range from
25 to 100 mg mL1, with linear equation of Y¼10.03Xþ5.00 and
Y¼9.20Xþ6.53 and regression coefﬁcient (r2) of 0.9950 and 0.9987,
for standard and sample curves, respectively (Fig. 5). The results
of linearity indicate parallelism among standard and sample curves,
which is important to conﬁrm validity of potency results. In addition,
the microbiological method was precise (repeatability¼2.0% and
intermediate precision¼1.9%) and accurate (mean recovery¼102.7%).
In addition, the central composite design allowed us to have a better
understanding of the inﬂuence of the volume of seeded culture
medium and inoculum amount on microbiological assay results.
According to our results, inoculum amount affects the inhibition zone
sizes more than the volume of seeded culture medium, as shown in
Figs. 2–4. However, the microbiological assay may be considered
robust to slight changes in these conditions.
Table 3
An incomplete quadratic model to explain the inhibition zone diameters based
on volume of seeded culture medium, proportion of inoculum and antibiotic
concentration.
Factors Model Coefﬁcients
Constant Linear 51.1987
Antibiotic concentration Linear 9.61206
Proportion of inoculum Linear 1.06944
Volume of medium Linear 25.6250
Volume of medium Quadratic 2.91667
This model showed good adjustment (p¼0.993 for lack-of-ﬁt and r2¼0.9198).
Fig. 4. Three-dimensional plots of the response surface for Y (inhibition zone
diameters). (A) Variation of response Y as a function of X1 (volume of seeded
culture medium) and X2 (proportion of inoculum). (B) Variation of the response Y
as a function of X1 (volume of seeded culture medium) and X2 (linezolid
concentration). (C) Variation of the response Y as a function of X1 (proportion of
inoculum) and X2 (linezolid concentration).
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Most of uncertainty in a microbiological assay is associated
with variability of inhibition zone diameters (within and between
plates). Lourenço [52] and Ghisleni et al. [21] describe procedures
to estimate the uncertainty of microbiological assay using analysis
of variance (ANOVA), using different experimental designs. Also,
uncertainty of microbiological assay may be estimated using
method validation data [48]. According to our results, linezolid
potency and its ﬁnal uncertainty were found to be 102.773.1%.
This uncertainty was comparable to those obtained for apramycin
(6.9–7.1%) [52], cefazolin (6.2–6.7%) [54], caspofungin (1.7%) [21],
and vancomycin (4.3%) [48]. This uncertainty was also compar-
able to those obtained from determination of linezolid by UV
spectrophotometry (2.1%) [4], and RP-UPLC (2.5%) (our results not
published yet).
The higher variability of microbiological assay may be
explained because of the complexity of diffusion of antimicrobial
agent and microbial growth. Several factors such as thickness of
seeded layer (among plates and lack of uniformity within plates),
amount of microorganism, composition of culture medium, varia-
bility of temperature and time of incubation, diffusion issues, and
others may affect the inhibition zone diameters, and consequently,
they will affect the measurement uncertainty of microbiological
assay [15]. However, further studies should be done to determine
the individual contribution of these factors to microbiological
assay's overall uncertainty.
4. Conclusion
A new microbiological assay for quantiﬁcation of linezolid was
developed and optimized. The optimized conditions employed
4 mL of antibiotic 1 medium inoculated with 1% of S. aureus sus-
pension, and linezolid in concentrations from 25 to 100 mg mL1.
The method was speciﬁc, linear, accurate, precise and robust.
The microbiological assay's overall uncertainty was comparable
to those obtained for other microbiological assays and for deter-
mination of linezolid by spectrophotometry and RP-UPLC. There-
fore, it is an acceptable alternative method for the routine quality
control of linezolid in injectable solution.
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of 4 mL and 1% of inoculum proportion.
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